These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1358 related articles for article (PubMed ID: 17296539)

  • 21. [Rasagiline in Parkinson's disease].
    Linazasoro G
    Neurologia; 2008 May; 23(4):238-45. PubMed ID: 18307054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.
    Youdim MB; Bar Am O; Yogev-Falach M; Weinreb O; Maruyama W; Naoi M; Amit T
    J Neurosci Res; 2005 Jan 1-15; 79(1-2):172-9. PubMed ID: 15573406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
    Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
    Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
    Palfreyman MG; McDonald IA; Zreika M; Cremer G; Haegele KD; Bey P
    J Neural Transm Suppl; 1993; 40():101-11. PubMed ID: 8294896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rasagiline in Parkinson's disease.
    Chahine LM; Stern MB
    Int Rev Neurobiol; 2011; 100():151-68. PubMed ID: 21971007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.
    Stocchi F
    Int J Clin Pract; 2006 Feb; 60(2):215-21. PubMed ID: 16451296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
    Elmer L; Schwid S; Eberly S; Goetz C; Fahn S; Kieburtz K; Oakes D; Blindauer K; Salzman P; Oren S; Prisco UL; Stern M; Shoulson I; ;
    J Neurol Sci; 2006 Oct; 248(1-2):78-83. PubMed ID: 16828804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rasagiline.
    Siddiqui MA; Plosker GL
    Drugs Aging; 2005; 22(1):83-91; discussion 93-4. PubMed ID: 15663351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
    Tolosa E; Stern MB
    Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of rasagiline in the treatment of Parkinson's disease.
    Leegwater-Kim J; Bortan E
    Clin Interv Aging; 2010 May; 5():149-56. PubMed ID: 20517484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease.
    Solís-García del Pozo J; Mínguez-Mínguez S; de Groot PW; Jordán J
    Expert Opin Drug Saf; 2013 Jul; 12(4):479-86. PubMed ID: 23634791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rasagiline. Parkinson's disease: a simple me-too.
    Prescrire Int; 2006 Dec; 15(86):220. PubMed ID: 17167927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
    Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
    Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.